Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
2
6
2023
pubmed:
9
2
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
This study was designed to assess healthcare resource utilization (HCRU) and costs in patients with newly diagnosed schizophrenia based on timing and context of long-acting injectable antipsychotic agent (LAI) initiation. Using claims data, patients (aged 18-40 years) with first schizophrenia diagnosis January 2013-September 2019 (index date), no LAI or oral antipsychotic agent claims during 12-month preindex period, and continuous benefit enrollment from 12 months before index date to 12 months after first LAI administration were identified. Patients were grouped based on timing [early (≤1 year after index date) vs. late] and circumstances [reactive (after schizophrenia-related event) vs. proactive] of LAI initiation. Of 1290 patients with at least one LAI claim, 306 met criteria for early ( n = 204; reactive, n = 107; proactive, n = 97) and late ( n = 102; n = 75; n = 27) initiation. HCRU and costs were numerically lower in early versus late groups, and significantly lower for proactive initiation in both groups. Comparing worst-case (late-reactive) and best-case (early-proactive) scenarios, the average annual cost difference was $7195.13 ( P = 0.0233), with major drivers being emergency department ($171.28; P < 0.05) and other outpatient ($2845.73; P < 0.00001) visits. In addition to the clinical advantages previously described in the literature, the proactive use of LAIs in early-phase schizophrenia is associated with lower healthcare costs.
Identifiants
pubmed: 36752713
doi: 10.1097/YIC.0000000000000452
pii: 00004850-202307000-00007
pmc: PMC10234320
doi:
Substances chimiques
Antipsychotic Agents
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-248Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383.
Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP (2008). The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61:1234–1240.
Cohen RA, Cha AE, Martinez ME, Terlizzi EP (2020). Health insurance coverage: early release of estimates from the National Health Interview Survey, 2019. National Center for Health Statistics. https://www.cdc.gov/nchs/nhis/healthinsurancecoverage.htm . [Accessed 22 August 2022]
Fitch K, Iwasaki K, Villa KF (2014). Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits 7:18–26.
Florida Medicaid Drug Therapy Management Program (2020). 2019–2020 Florida best practice psychotherapeutic medication guidelines for adults. Florida Agency for Health Care Administration, The University of South Florida. https://floridabhcenter.cbcs.usf.edu/wp-content/uploads/2021/04/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf . [Accessed 22 August 2022]
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858.
Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS (2018). Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 21:127–134.
IBM Watson Health (2020). IBM MarketScan Research Databases for life sciences researchers. IBM Corporation. https://www.ibm.com/downloads/cas/OWZWJ0QO .
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. (2015). Schizophrenia. Nat Rev Dis Primers 1:15067.
Kane JM, Schooler NR, Marcy P, Achtyes ED, Correll CU, Robinson DG (2019). Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 80:18m–12546.
Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. (2020). Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry 77:1217–1224.
Kane J, Mychaskiw M, Lim S, Suett M, Tian M, Park S, et al. (2021). Treatment journey of patients with schizophrenia from diagnosis to the successful implementation of treatment with a long-acting injectable antipsychotic agent [Poster]. In: 34th Annual European College of Neuropsychopharmacology Congress; 2–5 October 2021; Lisbon, Portugal.53:S567.
Keenan A, Lin D, Shepherd J, Bailey H, Benson C, Meakin S (2022). Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey. BMC Psychiatry 22:187.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al.; (Systematic Review) (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177:868–872.
Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jäger M (2013). Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 3:89–99.
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU (2013). Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74:957–965.
Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 8:387–404.
Munday J, Greene M, Chang E, Hartry A, Yan T, Broder MS (2019). Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin 35:1231–1239.
Patel KR, Cherian J, Gohil K, Atkinson D (2014). Schizophrenia: overview and treatment options. P T 39:638–645.
Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. (2017). Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence 11:619–629.
Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J (2021). Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull 47:1611–1620.
Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, et al. (2018). Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat 14:1463–1474.
Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 169:393–399.
Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L (2012). Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatr Dis Treat 8:375–385.
Stahl SM (2014). Long-acting injectable antipsychotics: shall the last be first? CNS Spectr 19:3–5.
Stevens GL, Dawson G, Zummo J (2016). Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry 10:365–377.
Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. (2015). Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of Schizophrenia. A randomized clinical trial. JAMA Psychiatry 72:822–829.
Taipale H, Tanskanen A, Correll CU, Tiihonen J (2022). Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry 9:271–279.
Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, et al. (2019). Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology 44:1036–1042.
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609.